Phase 4 Crohn's Disease and Colitis Trial, Recruiting NCT05481619 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 4 Crohn's Disease and Colitis Trial, Recruiting

NCT05481619
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with moderate to severe ulcerative colitis and for whom vedolizumab treatment has been indicated
  • People who are willing to take part in the study and sign the consent form
  • People who have never previously been treated with vedolizumab
  • People who have either never received biologic therapy, or who stopped a previous biologic therapy more than 12 weeks ago
  • People who have not taken antibiotics or probiotics in the past 4 weeks

Who may not be able to join:

  • People under 18 years of age
  • People who are pregnant or breastfeeding
  • People who would need the help of another person to complete the trial on their behalf, or who are otherwise unable to complete the trial independently
  • People with other health conditions that, in the opinion of the trial investigator, make participation unsuitable or could affect the ability to complete the study (confirm with trial site)
  • People who have taken antibiotics or probiotics within the past 4 weeks
  • People who have previously received vedolizumab treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Yan Chen, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Phone: 0086-13456820567

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 January 2021
Est. completion
1 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Remission rate of patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov